Guggenheim Maintains Neutral on Amgen, Lowers Price Target to $340

Benzinga Newsdesk www.benzinga.com Negative 79.0%

Neg 79% Neu 0% Pos 0%

Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price target from $351 to $340.